fda drug safety communication naion semaglutide 2025 Suboptimal therapeutic responses associated with in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials: Cell Reports Medicine Compounded Semaglutide & Tirzepatide 2025:

Results from the SELECT trial also indicated that a dose of 2.4mg of semaglutide has potential to combat kidney function decline among individuals with cardiovascular disease who are overweight or have obesity, but without diabetes

If this interests you, discuss it with your Belle Health provider to see if it aligns with your treatment plan

Key Take-Home Messages GLP-1 medications have evolved from twice-daily injections for diabetes to versatile, once-weekly (and soon once-daily pill) options that tackle hyperglycemia, weight, and cardiovascular risk simultaneously

Excited to share our latest publication in Innovative Food Science and Emerging Technologies: Antioxidant assessment of a glutathione-rich extract obtained from electroporated cells of Saccharomyces cerevisiae in white grape must In this work, we explored a natural and sustainable alternative to reduce sulfite use in winemaking

Weightlifting helps preserve and even build muscle mass, ensuring that your body composition improves as you lose weight